This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Top Research Reports for JPMorgan Chase, Netflix & AbbVie
by Mark Vickery
JPMorgan's year-to-date gains, NII growth outlook and investment banking pipeline headline today's standout Zacks research picks.
JPMNegative Net Change EQIXPositive Net Change NFLXNegative Net Change ALLPositive Net Change RSGPositive Net Change ABBVPositive Net Change OVBCPositive Net Change
consumer-discretionary finance pharmaceuticals
Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI
by Aparajita Dutta
LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.
JNJPositive Net Change LLYPositive Net Change NVDANegative Net Change ABBVPositive Net Change XLVPositive Net Change VHTPositive Net Change PLTRNegative Net Change
etfs pharmaceuticals
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
by Zacks Equity Research
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
AZNPositive Net Change MRKPositive Net Change ADMAPositive Net Change EDITNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
by Zacks Equity Research
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
NVSPositive Net Change BAYRYPositive Net Change FOLDPositive Net Change RNANegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
by Sundeep Ganoria
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
REGNPositive Net Change ABBVPositive Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
by Kinjel Shah
Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
AZNPositive Net Change BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Top Analyst Reports for Visa, Merck & Southern Company
by Mark Vickery
Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.
SOPositive Net Change VPositive Net Change ETRPositive Net Change MRKPositive Net Change TTWOPositive Net Change CHCIPositive Net Change CMTVNo Net Change GEHCPositive Net Change
business-services construction finance pharmaceuticals utilities
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
by Zacks Equity Research
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
ADMAPositive Net Change EDITNegative Net Change COGTPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
MRKPositive Net Change GILDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
by Zacks Equity Research
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
by Kinjel Shah
LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 blockbusters.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change ADVMNegative Net Change
pharmaceuticals
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
by Zacks Equity Research
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
JNJPositive Net Change MRKPositive Net Change UTHRPositive Net Change
pharmaceuticals
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
by Zacks Equity Research
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
NVOPositive Net Change VNDANegative Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
by Kinjel Shah
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
AZNPositive Net Change JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
by Zacks Equity Research
Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms
JNJPositive Net Change ALKSPositive Net Change BAYRYPositive Net Change FOLDPositive Net Change
biotechnology medical pharmaceuticals
Pharma ETF (FTXH) Hits New 52-Week High
by Sanghamitra Saha
Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.
FTXHPositive Net Change
etfs pharmaceuticals
Bull of the Day: Collegium Pharmaceutical (COLL)
by Shaun Pruitt
This medical stock has been seeing strong momentum but is still cheaply valued and may serve as a further hedge against recent market jitters.
COLLPositive Net Change
earnings investing medical pharmaceuticals
Top Research Reports for Microsoft, Amazon.com & Eli Lilly
by Mark Vickery
Microsoft shines in Zacks' top picks as strong cloud and AI momentum drive standout quarterly results and reinforce long-term growth potential.
AMZNPositive Net Change MSFTNegative Net Change LLYPositive Net Change YUMPositive Net Change SCHWPositive Net Change CNQNegative Net Change
computers pharmaceuticals retail
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
by Zacks Equity Research
Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.
RHHBYPositive Net Change LLYPositive Net Change ALKSPositive Net Change BAYRYPositive Net Change
medical pharmaceuticals
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
by Zacks Equity Research
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
NVOPositive Net Change ADMAPositive Net Change ARQTPositive Net Change VTYXNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
by Kinjel Shah
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change CDTXNegative Net Change
pharmaceuticals
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
by Kinjel Shah
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change
pharmaceuticals
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
by Zacks Equity Research
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
GSKPositive Net Change ADMAPositive Net Change ALECPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals